Literature DB >> 30993488

Genetic counseling referral for ovarian cancer patients: a call to action.

Christine Garcia1, Kara Harrison2, Kari L Ring1, Mackenzie W Sullivan3,4, Lisa A Rauh1, Susan C Modesitt1.   

Abstract

The hereditary contribution to ovarian cancer has been increasingly recognized over the past decade, with a 2014 Society of Gynecologic Oncology (SGO) recommendation for all women with epithelial ovarian cancer to be considered for genetic testing. The objective of the study was to determine if disparities exist in genetic referrals and characterize referral patterns over time. A retrospective cohort study included all women diagnosed with invasive epithelial ovarian cancer at the University of Virginia from 2004 to 2015. Clinicopathologic data were abstracted from the electronic medical record and analyzed for association with genetic referral and testing. We identified 696 cases, with a median age of 62 years and a median follow up of 25.2 months (range 1-115). Thirty-four percent were referred for genetic counseling with an 80% genetic testing rate in those women. Referrals increased from a rate of 8% in 2004 to 68% in 2015. On multivariable analysis, papillary serous histology (OR 1.6, 95% CI 1.0-2.6), stage III disease (OR 3.4, 95% CI 1.6-7.5), ovarian cancer family history (OR 2.6, 95% CI 1.5-4.6), breast cancer family history (OR 1.7, 95% CI 1.1-2.5), and diagnosis after 2014 (OR 2.3, 95% CI 1.3-4.1) remained significantly associated with genetics referral. Older age and living > 100 miles away were associated with decreased referral (OR 0.97, 95% CI 0.95-0.99 per year and OR 0.49, 95% CI 0.28-0.86). As only 68% of women with epithelial ovarian cancer were referred in 2015 innovative strategies such as Medicare coverage for counseling are still needed to universalize testing.

Entities:  

Keywords:  Familial cancer; Genetic counseling; Hereditary cancer syndrome; Ovarian cancer

Mesh:

Year:  2019        PMID: 30993488     DOI: 10.1007/s10689-019-00129-5

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  19 in total

1.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.

Authors:  Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.

Authors:  Denise Uyar; Jamie Neary; Amy Monroe; Melodee Nugent; Pippa Simpson; Jennifer L Geurts
Journal:  Gynecol Oncol       Date:  2018-04-10       Impact factor: 5.482

3.  Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.

Authors:  Casey L Swanson; Amanika Kumar; Joy M Maharaj; Jennifer L Kemppainen; Brittany C Thomas; Megan R Weinhold; Kristine M Slaby; Kristin C Mara; Myra J Wick; Jamie N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2018-02-03       Impact factor: 5.482

4.  Linkage of early-onset familial breast cancer to chromosome 17q21.

Authors:  J M Hall; M K Lee; B Newman; J E Morrow; L A Anderson; B Huey; M C King
Journal:  Science       Date:  1990-12-21       Impact factor: 47.728

Review 5.  Current and future role of genetic screening in gynecologic malignancies.

Authors:  Kari L Ring; Christine Garcia; Martha H Thomas; Susan C Modesitt
Journal:  Am J Obstet Gynecol       Date:  2017-04-12       Impact factor: 8.661

6.  Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.

Authors:  Nicoletta Colombo; Gloria Huang; Giovanni Scambia; Eva Chalas; Sandro Pignata; James Fiorica; Linda Van Le; Sharad Ghamande; Santiago González-Santiago; Isabel Bover; Begoña Graña Suárez; Andrew Green; Philippe Huot-Marchand; Yann Bourhis; Sudeep Karve; Christopher Blakeley
Journal:  J Clin Oncol       Date:  2018-03-20       Impact factor: 44.544

7.  Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Authors:  Jonathan A Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Philip Rowe; Elizabeth Lowe; Darren Hodgson; Mika A Sovak; Ursula Matulonis
Journal:  Lancet Oncol       Date:  2016-09-09       Impact factor: 41.316

8.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

9.  ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.

Authors: 
Journal:  Obstet Gynecol       Date:  2009-04       Impact factor: 7.661

10.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

Authors:  Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos
Journal:  Oncotarget       Date:  2016-03-22
View more
  3 in total

1.  Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers.

Authors:  Kara N Maxwell; Brandon M Wenz; Abha Kulkarni; Bradley Wubbenhorst; Kurt D'Andrea; Benita Weathers; Noah Goodman; Joseph Vijai; Jenna Lilyquist; Steven N Hart; Thomas P Slavin; Kasmintan A Schrader; Vignesh Ravichandran; Tinu Thomas; Chunling Hu; Mark E Robson; Paolo Peterlongo; Bernardo Bonanni; James M Ford; Judy E Garber; Susan L Neuhausen; Payal D Shah; Angela R Bradbury; Angela M DeMichele; Kenneth Offit; Jeffrey N Weitzel; Fergus J Couch; Susan M Domchek; Katherine L Nathanson
Journal:  JCO Precis Oncol       Date:  2020-08-19

2.  Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.

Authors:  Jenny Lin; Ravi N Sharaf; Rachel Saganty; Danyal Ahsan; Julia Feit; Andrea Khoury; Hannah Bergeron; Eloise Chapman-Davis; Evelyn Cantillo; Kevin Holcomb; Stephanie V Blank; Ying Liu; Charlene Thomas; Paul J Christos; Drew N Wright; Steven Lipkin; Kenneth Offit; Melissa K Frey
Journal:  Gynecol Oncol       Date:  2021-05-19       Impact factor: 5.304

3.  Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.

Authors:  Kristin R Muessig; Jamilyn M Zepp; Erin Keast; Elizabeth E Shuster; Ana A Reyes; Briana Arnold; Chalinya Ingphakorn; Marian J Gilmore; Tia L Kauffman; Jessica Ezzell Hunter; Sarah Knerr; Heather S Feigelson; Katrina A B Goddard
Journal:  Hered Cancer Clin Pract       Date:  2022-02-10       Impact factor: 2.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.